Radiologically isolated syndrome (RIS) represents a unique window into the earliest detectable stages of potential neurological disease, discovered when brain or spinal cord imaging reveals lesions characteristic of multiple sclerosis—yet the person has never experienced typical neurological symptoms.

Understanding a Silent Discovery: When Brain Scans Reveal Unexpected Findings

The main goal when managing radiologically isolated syndrome is to decide whether active monitoring alone is sufficient or whether early intervention might help prevent future neurological symptoms. Treatment approaches depend heavily on individual risk factors, the appearance of lesions on imaging, and laboratory findings that might predict disease progression. The medical community recognizes that RIS sits at a crossroads: some people will develop clinical multiple sclerosis over time, others may show new imaging changes without symptoms, and still others remain stable for years.^[2][6]

Standard treatment protocols borrowed from multiple sclerosis exist, and they involve medications that modify the immune system’s activity. At the same time, researchers are actively investigating new therapeutic approaches through clinical trials, exploring whether early treatment can delay or prevent the onset of symptoms. There is no universal consensus on how to treat every person with RIS, which makes individualized care essential. Each case requires careful discussion between the patient and neurologist about the potential benefits and risks of starting therapy versus careful observation with regular imaging.^[6]

The diagnosis of RIS has evolved considerably since it was first formally defined in 2009. Originally, doctors only considered it when brain scans were obtained completely by accident—for example, during evaluation of headaches, head trauma, or dizziness. More recently, the definition has expanded to include people who have certain vague symptoms like heat intolerance, mood changes, or cognitive difficulties, but no clear neurological events that would traditionally suggest multiple sclerosis. These symptoms overlap with what some call the “MS prodrome,” suggesting that RIS might simply be an early form of disease that hasn’t yet caused obvious clinical problems.^[1][8]

Standard Treatment Approaches: Observation and Disease-Modifying Therapies

Currently, there is no cure for radiologically isolated syndrome, and the standard approach often begins with careful observation rather than immediate medication. For many people with RIS, especially those without certain high-risk features, regular monitoring through MRI scans and clinical checkups may be the most appropriate strategy. This approach allows doctors to track whether new lesions appear or existing ones change, which could signal progression toward symptomatic multiple sclerosis.^[2][9]

When treatment is considered necessary, the medications used are typically the same disease-modifying therapies (drugs that alter the course of disease by affecting the immune system) approved for multiple sclerosis. These include injectable medications, oral tablets, and intravenous infusions that work by dampening the immune system’s attack on the protective coating around nerve fibers called myelin. The rationale behind using these medications is to reduce inflammation in the central nervous system before it causes noticeable symptoms.^[6]

The decision to start disease-modifying therapy depends on several factors identified as increasing the risk of progression. People with spinal cord lesions, younger age at diagnosis, presence of abnormal proteins called oligoclonal bands (immune system markers found in spinal fluid) in cerebrospinal fluid, or evidence of new lesion development on follow-up scans are considered at higher risk for developing clinical symptoms. For these individuals, doctors may recommend beginning treatment earlier rather than waiting for symptoms to appear.^[1][6]

Disease-modifying therapies carry potential side effects that must be weighed against their benefits. Injectable medications can cause skin reactions at injection sites and flu-like symptoms. Oral medications may affect liver function, increase infection risk, or cause digestive problems. Intravenous therapies require monitoring for infusion reactions and can suppress parts of the immune system, making infections more likely. Blood tests and regular medical supervision are necessary when taking any of these medications to catch and manage side effects early.^[6]

Some neurologists advocate for early treatment based on two management philosophies. The first emphasizes that treating before symptoms appear might prevent irreversible nerve damage that could occur silently. The second approach prioritizes observation, arguing that not everyone with RIS will develop symptomatic disease, and exposing people to medication side effects when they might never need treatment could cause more harm than good. Studies following people with RIS over two years show that about one-third develop neurological symptoms, one-third develop new imaging findings without symptoms, and one-third show no change at all.^[2][9]

Emerging Treatments Being Studied in Clinical Trials

Researchers are actively investigating whether early intervention with disease-modifying therapies can prevent or delay the onset of multiple sclerosis symptoms in people with radiologically isolated syndrome. Two randomized clinical trials have recently provided important evidence about the impact of early treatment. These studies represent a significant advancement in understanding whether medication can change the natural course of RIS before symptoms develop.^[10]

Clinical trials for RIS typically test medications that are already approved for multiple sclerosis but are being evaluated specifically in people who have not yet experienced clinical symptoms. These studies often compare active medication against placebo or observation alone. The trials measure outcomes such as time until first clinical symptoms appear, development of new lesions on MRI scans, and changes in neurofilament light chain levels (proteins released when nerve fibers are damaged that serve as a biomarker of ongoing injury) in the blood.^[6]

Phase III clinical trials, which represent the stage where researchers compare new treatments or new uses of existing treatments against standard care in larger groups of people, have shown promising preliminary results. Some trials have demonstrated that early treatment with disease-modifying therapies can reduce the risk of developing a first clinical event suggestive of multiple sclerosis. These findings have sparked debate within the neurological community about whether treatment recommendations for RIS should change to favor earlier intervention.^[10]

Beyond traditional disease-modifying therapies, researchers are exploring how advanced imaging techniques might better identify which people with RIS need treatment most urgently. Some studies use specialized MRI methods that can detect blood vessels running through lesions, which is a distinguishing feature of multiple sclerosis-related inflammation. These advanced imaging approaches are being tested to determine whether they can improve diagnostic accuracy and help predict who will progress to symptomatic disease.^[2][9]

Clinical trial eligibility for people with RIS typically requires meeting specific diagnostic criteria published in 2023, which mirror many elements of the McDonald criteria used to diagnose multiple sclerosis. Participants must have characteristic lesion patterns on MRI, no history of typical neurological symptoms, and no alternative explanation for the brain abnormalities. Many trials also require certain laboratory findings, such as oligoclonal bands in cerebrospinal fluid or evidence of new lesion development on follow-up scans, as these features identify people at highest risk of progression.^[1][8]

Research studies are being conducted at specialized multiple sclerosis centers across the United States, Europe, and other regions. These centers often participate in multicenter research consortia, such as the RIS Consortium, which pools data from many institutions to better understand the natural history of the condition and evaluate treatment effectiveness. People interested in participating in research can discuss trial opportunities with their neurologist or contact major academic medical centers with dedicated MS programs.^[6]

Investigators are also examining biomarkers beyond traditional MRI findings that might predict disease progression. Elevated serum neurofilament light chain levels, for example, have been shown to increase years before MS symptoms develop, suggesting that blood tests might eventually complement imaging in risk assessment. These biomarkers could help doctors identify which people with RIS would benefit most from early treatment versus continued observation.^[6][12]

The mechanism of action of treatments being studied involves modulating or suppressing specific parts of the immune system that attack myelin and nerve fibers. Some medications prevent certain immune cells from entering the central nervous system. Others deplete specific populations of immune cells that drive inflammation. Still others interfere with signaling pathways that immune cells use to coordinate attacks on nervous tissue. By intervening at this early stage, researchers hope to prevent the accumulation of irreversible damage that leads to disability in symptomatic MS.^[6]

Most common treatment methods

• Observation and surveillance
  • Regular MRI scanning to monitor for new lesion development or changes in existing lesions
  • Clinical examinations to assess for emerging neurological symptoms
  • Appropriate for individuals without high-risk features who show stable imaging over time
  • Allows avoidance of medication side effects in people who may never develop symptoms
• Disease-modifying immunotherapies
  • Injectable medications that reduce immune system activity and inflammation in the central nervous system
  • Oral therapies that modulate immune cell function or prevent immune cells from entering the brain and spinal cord
  • Intravenous infusions that deplete specific immune cell populations or block inflammatory pathways
  • Recommended particularly for people with spinal cord lesions, oligoclonal bands, or evidence of new lesion formation
• Advanced diagnostic imaging
  • Specialized MRI techniques that help distinguish MS-related lesions from other causes of white matter abnormalities
  • Serial imaging to document dissemination in time, meaning new lesions appearing on follow-up scans
  • Spinal cord imaging to identify lesions that increase risk of progression to symptomatic MS
• Cerebrospinal fluid analysis
  • Lumbar puncture to test for oligoclonal bands, which are abnormal immune proteins associated with higher risk
  • Analysis helps determine whether someone meets criteria for more aggressive monitoring or treatment
  • Blood tests to rule out other conditions that might explain imaging findings